Evidence map›Paper›PMID 41796991›Full record

Observational studyJournal of gynecologic oncology2026

Validation of molecular classification on diagnostic biopsy in endometrial carcinoma: the first step for a tailored approach.

Giulia Spagnol, Matteo Marchetti, Tommaso Vezzaro, Eleonora Panizzolo, Sofia Bigardi, Orazio De Tommasi, Angela Guerriero, Lara Alessandrini, Marco Noventa, Roberto Tozzi and 1 more

Abstract readObservational StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giulia Spagnol *Division of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0000-0003-3525-0571
Matteo Marchetti *Division of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0009-0001-4795-9150
Tommaso VezzaroDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0009-0003-6157-3451
Eleonora PanizzoloDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0009-0001-2688-097X
Sofia BigardiDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0009-0004-6873-5924
Orazio De TommasiDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0000-0001-5890-9792
Angela GuerrieroPathological Anatomy Unit, Department of Medicine DIMED, University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0001-9981-7448
Lara AlessandriniPathological Anatomy Unit, Department of Medicine DIMED, University of Padova, Padova, Italy.ORCID https://orcid.org/0000-0002-2467-1058
Marco NoventaDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0000-0002-7809-6001
Roberto TozziDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy. roberto.tozzi@unipd.it.ORCID https://orcid.org/0000-0001-6123-1628
Carlo SaccardiDivision of Women and Children, Department of Gynecology and Obstetrics, Padova University Hospital, Padova, Italy.ORCID https://orcid.org/0000-0001-7476-997X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo validate the concordance of histologic subtype, tumor grade, molecular classification, and risk group between pre-operative endometrial biopsy and final hysterectomy specimens in patients with endometrial cancer (EC).

methodsThe PReOperative MOlecular Biopsy (ProMobi) study is a prospective, monocentric, observational study conducted from September 2023 to March 2024. All patients with suspicious finding for EC were included. Diagnosis was achieved by a pre-operative biopsy. On the latter, histopathology analysis, tumor grade, immunohistochemical (IHC) markers, molecular classification and risk group were determined. The same was performed on the final hysterectomy. Concordance was evaluated using Cohen's κ statistic.

resultsA total of 50 consecutive patients were included. Molecular classification showed perfect concordance for

conclusionThis study demonstrates a high concordance in molecular classification, histotype, tumor grade and risk group between hysteroscopic biopsy and hysterectomy specimens. These findings establish that a personalized surgical approach to EC patients can be guided by molecular classification on pre-operative biopsy.

Indexed as

Endometrial NeoplasmsAdultAgedBiomarkers, TumorBiopsyEndometriumFemaleHumansHysterectomyMiddle AgedMutationNeoplasm GradingProspective StudiesBiomarkers, TumorAdjuvant TherapyBiopsyEndometrial CarcinomaPeroMisE

Identifiers

PMID41796991
PMCPMC13365767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.